FindTrial
Sign In

Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy

Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000539
Enrollment
Unknown
Registered
2009-09-30
Start date
2004-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic Disease

Interventions

S:Patients receive tacrolimus combined with prednison for six months
L:Patients receive tacrolimus combined with prednison for 24 months

Sponsors

Second Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of primary NS; 2. Renal biopsy-proven IMN and diagnosis of class I to III; 3. Scr<221umol/L; 4. No therapy with other immunosuppressive or non-steroidal anti-inflammatory drugs prior to the inclusion in the study.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Combined with serious complications such as severe infection, tumor, HIV infection, and active HBV infection; 3. Other serious renal disease including diabetic nephropathy; 4. Known allergy to the calcineurin inhibitors.

Design outcomes

Primary

MeasureTime frame
Serum albumin level;24hours urinary protein;—

Countries

China

Contacts

Public ContactLi-ning Miao
miaolining@yahoo.com.cn+86 13904303985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026